Doug Elmendorf to head CBO
Having started his non-academic career as a Congressional Budget Office analyst whose purview included health care reform, Douglas Elmendorf is returning to the agency to succeed Peter Orszag as director. During his first stint at the budget agency in 1993-95, Elmendorf's output included analysis of the economic effects of the Clinton Administration health care proposals and options for controlling private health insurance premiums. Since leaving CBO in 1995, the Harvard-educated economist has served in senior positions at Treasury, the Federal Reserve Board and the Council of Economic Advisers. He currently is director of the Hamilton Project at the Brookings Institution. Orszag, who will lead the Office of Management and Budget in the Obama Administration, was the first director of that project, which generates ideas for promoting broad-based economic growth. CBO has helped kicked off the health reform debate with a late December report scoring the budget impact of various reform options. Speaker of the House Nancy Pelosi announced the selection of Elmendorf Dec. 30
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.